Search the Newsreel

T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G

T. Rowe Price Associates has disclosed a 6.0% beneficial ownership stake in Celldex Therapeutics Inc. (CLDX) through a Schedule 13G filing. The firm reported holding 4,686,187 shares of common stock, with sole voting power over 4,683,226 shares and sole dispositive power over all 4,686,187 …

Handelsbanken Fonder AB Purchases 48,876 Shares of Willdan Group, Inc. $WLDN

Handelsbanken Fonder AB increased its stake in Willdan Group, Inc. by 34.3% in the second quarter, acquiring an additional 48,876 shares to bring its total ownership to 191,532 shares. This move is part of a broader trend of institutional investors, including Swedbank and Dimensional …

Willdan Group (WLDN) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 5:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Mike BieberExecutive Vice President and Chief Financial Officer - Kim EarlyVice President - Al Kaschalk TAKEAWAYS Contract Revenue -- $231.0 million, representing …

Celldex Therapeutics (CLDX) Reported Wider Losses, Is It Still Undervalued?

Celldex Therapeutics (CLDX) recently reported wider losses and lower revenue for Q2 and H1 2026, yet its stock has seen significant recent gains. While the company trades at a 4.9x Price-to-Book multiple, suggesting it's overvalued compared to peers, a Discounted Cash Flow (DCF) model …

Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX

Sei Investments Co. recently acquired a new stake of 38,152 shares in Celldex Therapeutics, Inc., valued at approximately $1.21 million. This comes as several other hedge funds have also adjusted their positions in the biopharmaceutical company. Celldex Therapeutics reported better-than-expected quarterly earnings and has …

Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress

Celldex Therapeutics (CLDX) reported wider Q2 and first-half losses totaling US$73.5 million and US$152.19 million, respectively, yet its stock rose by 10.7%. This increase is attributed to positive Phase 1 data for bispecific antibody CDX-622 and continued Phase 3 progress for barzolvolimab, despite minimal …

HC Wainwright Issues Optimistic Forecast for CLDX Earnings

Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX

Quantinno Capital Management LP significantly increased its stake in Celldex Therapeutics (NASDAQ:CLDX) by 178.7% in the first quarter, purchasing an additional 42,158 shares to own a total of 65,744 shares valued at $2.09 million. This move comes as institutional investors continue to adjust their …

Janus Henderson Group PLC Sells 22,399 Shares of Willdan Group, Inc. $WLDN

Janus Henderson Group PLC significantly reduced its stake in Willdan Group, Inc. (NASDAQ:WLDN) by 79%, selling 22,399 shares and retaining 5,961 shares valued at $456,000. Institutional investors now collectively own 72.29% of WLDN, with several other funds adjusting their positions. Despite the sale, Willdan …

Willdan Group (WLDN) Reports Stronger Earnings And Guidance, Is The Valuation Gap Still Compelling?

Lloyds Banking Group (LSE:LLOY) Chief Risk Officer Exit Sets Up 2026 Leadership Shift

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Lloyds Banking Group (LSE:LLOY) plans for Group Chief Risk Officer Stephen Shelley to retire in October 2026. Shelley is set to join Legal …

Why Willdan Group (WLDN) Is Up 25.8% After Raising 2026 Revenue Targets And Posting Record EPS

Willdan Group (WLDN) saw its stock rise by 25.8% after reporting strong second-quarter 2026 results, including record diluted EPS of US$1.58 and increased sales. The company also raised its 2026 net revenue targets to US$415 million to US$430 million, driven by growth in commercial …

Celldex Therapeutics (CLDX) Stock Looks Rich On Book Value But Strong On Returns

Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Celldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. This places the stock's …

Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?

Celldex Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue falling to US$0.022 million and net loss widening to US$73.5 million, while loss per share from continuing operations increased to US$0.94. Over the first half of 2026, revenue slipped to just US$0.037 million as …

Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Celldex Therapeutics stock has more than doubled over the past year, yet its broader valuation checks lean expensive rather than cheap, which raises …

What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Celldex Therapeutics (NasdaqCM:CLDX) reported updated clinical pipeline data, including positive Phase 1 results for bispecific antibody CDX-622. The company outlined progress on ongoing Phase 3 …

Lloyds (LSE:LLOY) Stock Looks Fully Valued After A 217% Run

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Lloyds Banking Group stock has delivered very strong returns over the past five years, yet the main valuation checks send mixed messages. The Excess …

Celldex Therapeutics (NASDAQ:CLDX) Issues Earnings Results, Beats Estimates By $0.12 EPS

Celldex Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.07, Implies 40% Upside

The average 12-month price target for Celldex Therapeutics, Inc. (CLDX) stock has been raised from $57.07 to $58.07 by 15 analysts, with individual forecasts ranging from $38 to $100 per share. This new target suggests a potential upside of approximately 40% based on the …

Willdan Group (WLDN) Stock Reprices Higher On Record Margin Execution

Willdan Group: Discounted AI Enabler - Accelerating Utility/Data Center Monetization Prospects (NASDAQ:WLDN)

Willdan Group (WLDN) is identified as a "Great Buy" due to its role as an AI enabler, evidenced by accelerating new bookings and strong H1'26 performance leading to twice-raised FY2026 guidance. The stock is currently undervalued with a cheap EV/EBITDA compared to peers, despite …

Willdan Group (NASDAQ: WLDN) grows Q2 2026 earnings and acquires Burton

Willdan Group (NASDAQ: WLDN) reported significant growth in its Q2 2026 earnings and revenue, with contract revenue increasing by 33.2% year-over-year to $231.0 million and net income rising by 57.7% to $24.3 million. This performance was driven by increased demand in both its Energy …

Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Barclays Forecasts Strong Price Appreciation for Celldex Therapeutics (NASDAQ:CLDX) Stock

Willdan Group, Inc reports results for the quarter ended June 30 - Earnings Summary

Willdan Group, Inc. has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides an overview of the company's financial performance during this period. Readers can access the full report via TradingView.

Willdan Group Inc (WLDN) Stock News Today

This article provides recent news and financial data for Willdan Group Inc (WLDN), including its current stock price, market cap, and P/E ratio. The primary news item highlighted is Willdan's Q2 FY2026 earnings report, which shows a 23.5% net revenue growth driven by energy …

Willdan Group, Inc. $WLDN Position Increased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP increased its stake in Willdan Group, Inc. (NASDAQ:WLDN) by 7.5% during the first quarter, now owning 308,947 shares valued at $23.65 million. Other institutional investors also adjusted their positions, and despite some analyst downgrades, the stock has an average "Hold" …

Willdan Group (NASDAQ:WLDN) Shares Gap Up on Strong Earnings

Willdan Group, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:WLDN) 2026-08-07

Willdan Group (WLDN) reported a strong second quarter for 2026, with revenue significantly exceeding estimates and profitability improving sharply. The company saw substantial increases in revenue, net income, and diluted earnings per share, leading to a 13.75% rise in its stock after market close. …

Willdan Group Inc (WLDN) (Q2 2026) Earnings Call Highlights: Record Revenue and EBITDA, Raised ...

Willdan Group Inc. (WLDN) reported a record second quarter for 2026, with contract revenue up 33% year-over-year to $231 million and adjusted EBITDA increasing 51% to a record $33 million. The company raised its full-year 2026 financial targets, expecting net revenue between $415 million …

Celldex Therapeutics earnings beat by $0.12, revenue fell short of estimates

Willdan Group, Inc. (WLDN) stock price, news, quote and history

This article provides a detailed financial overview of Willdan Group, Inc. (WLDN), including its stock price, historical data, key financial metrics, and analyst ratings. It highlights the company's business segments in energy and engineering consulting, its performance compared to the S&P 500, and its …